![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Xtant Medical, Vivex Enter Distribution Agreement
Xtant Medical, Vivex Enter Distribution Agreement
![correct_handshake.gif](https://www.fdanews.com/ext/resources/test/Device_Images/handshake.gif?t=1576815772&width=430)
March 25, 2016
Xtant Medical Holdings is stepping into the cellular bone graft market by entering a distribution agreement with Vivex Biomedical, with its sights set on broadening its existing biologics portfolio.
Under the agreement, Vivex will process the cellular bone allograft OsteoVive, and Xtant will distribute the bone graft nationally.
Financial terms of the agreement were not disclosed.
The cellular allograft market reached roughly $252 million last year, and is expected to yield nearly $400 million in 2019, according to BioMedGPS.—Anisa Jibrell
Upcoming Events
-
21Oct